Renovaro Biosciences's market cap is currently ―. The company's EPS TTM is $-0.652; its P/E ratio is -3.71; Renovaro Biosciences is scheduled to report earnings on May 15, 2023, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	$ 61.22K	$ 246.08K	$ 53.31K	$ 53.31K
Gross Profit	-	$ 61.22K	$ 246.08K	$ 53.31K	$ 53.31K
EBIT	$ -4.27M	$ -9.00M	$ -22.94M	$ -4.06M	$ -4.37M
EBITDA	$ -4.04M	$ -8.81M	$ -22.79M	$ -3.96M	$ -4.34M
Net Income Common Stockholders	$ -4.53M	$ -9.18M	$ -23.20M	$ -4.33M	$ -4.46M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 243.98K	$ 523.47K	$ 1.87M	$ 2.95M	-
Total Assets	$ 58.02M	$ 57.56M	$ 58.30M	$ 78.20M	-
Total Debt	$ 7.39M	$ 4.60M	$ 5.59M	$ 7.04M	$ 0.00
Net Debt	$ 7.15M	$ 4.07M	$ 3.72M	$ 4.09M	$ 0.00
Total Liabilities	$ 14.42M	$ 10.82M	$ 11.80M	$ 12.60M	-
Stockholders Equity	$ 43.60M	$ 46.75M	$ 46.50M	$ 66.13M	-
Cash Flow	-
Free Cash Flow	$ -3.19M	$ -2.78M	$ -2.27M	$ -3.31M	$ -3.41M
Operating Cash Flow	$ -3.15M	$ -2.78M	$ -2.26M	$ -3.31M	$ -3.38M
Investing Cash Flow	$ -57.33K	$ -1.06M	$ -6.14K	-	$ -23.63K
Financing Cash Flow	$ 2.85M	$ 2.56M	$ 1.25M	$ 2.11M	$ -466.63K

Currency in USD

Renovaro Biosciences Earnings and Revenue History

Income Statement >

Renovaro Biosciences Debt to Assets

Balance Sheet >

Renovaro Biosciences Cash Flow

Cash Flow >

Renovaro Biosciences Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing